Primaquine Enantiomers in G6PD Deficient Human Volunteers

Metabolism and Pharmacokinetics of Primaquine Enantiomers in G6PD Deficient Human Volunteers Receiving a Five Day Dose Regimen

This study is a single center, prospective, cross-over phase 1 trial. Eighteen subjects will be enrolled in the study evaluating the metabolism, pharmacokinetic behavior and tolerability of primaquine enantiomers and placebo over the course of 5 days.

Each subject will receive a 15 mg dose of one enantiomer (SPQ or RPQ or Placebo) daily for up to 5 days, with careful monitoring of hematological parameters before and after each dose. In addition to the general CMP14 safety criteria, any subject who displays a fractional hemoglobin drop of 15% below his/her baseline value, then drug administration will stop (e.g. for baseline Hgb of 14 g/dL, if there is at any point a decrease of 2.1 g/dL). Hematocrit will be similarly monitored, with proportional stop criteria. Elevation in total bilirubin to 2.0 mg/dL or greater will also be used as a stopping criterion. After stopping drug administration (5 days or whenever stop criteria are met), subjects will have a 3-week washout period, and the study repeated with the other enantiomer, and similarly with Placebo.

Inclusion Criteria:

• G6PD deficient, otherwise normal healthy adults aged 18 to 65

Exclusion Criteria:

• Known history of liver, kidney or hematological disease (other than G6PD deficiency)
• Known history of cardiac disease, non-sinus rhythm arrhythmia or QT prolongation
• Autoimmune disorders
• Report of an active infection
• Subject is pregnant or breast-feeding, or is expecting to conceive during the study.